GMAB
Genmab AS
35.60$
+0.6%
vs. previous close
Closing price · As of: Sep 29, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 96.5% | 94.0% | 93.5% | 91.8% | 87.9% | 92.2% | 88.9% | 92.3% | 93.7% | 93.9% | 60.8% | 22.4% | |
| 12.5% | 22.4% | 5.9% | 20.4% | 6.3% | 23.5% | 34.3% | 36.4% | 32.8% | 42.1% | 21.5% | 13.3% | |
| 92.8% | 89.5% | 74.9% | 82.1% | 72.2% | 72.4% | 76.0% | 78.5% | 74.1% | 79.7% | 46.1% | 13.3% | |
| 3.7% | 4.5% | 18.6% | 8.8% | 15.7% | 19.7% | 11.6% | 13.7% | 19.0% | 14.0% | 14.6% | 8.9% | |
| – | 0.0% | 0.0% | 0.0% | 0.0% | -68.7% | -1.2% | -0.1% | -0.5% | 0.2% | 0.1% | 0.1% | |
| – | 0.7% | 0.6% | 1.7% | 1.9% | 2.7% | 3.5% | 4.0% | 4.4% | – | – | – | |
| – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | 0.0% | 5.5% | 2.8% | |
| 2.2% | 4.9% | 3.5% | 1.9% | 5.6% | 3.1% | 1.6% | 1.0% | 0.5% | 0.3% | 26.9% | 70.9% | |
| 29.1% | 10.7% | 7.9% | 5.0% | 5.3% | 7.2% | 9.6% | 9.9% | 9.4% | 10.4% | 19.9% | 54.6% | |
| 22.9% | 10.6% | 7.9% | 5.0% | 5.2% | 6.2% | 5.9% | 6.4% | 6.1% | 7.0% | 11.6% | 11.1% | |
| 0.0% | 0.0% | 1.2% | 0.0% | 0.0% | 0.2% | 0.2% | 0.3% | 0.2% | 0.3% | 0.2% | 2.3% | |
| 3.7% | 0.8% | 0.4% | 8.8% | 15.7% | 19.7% | 0.7% | 1.4% | 5.7% | 6.5% | – | 8.3% | |
| – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | 38.9% | |
| 70.9% | 89.3% | 92.1% | 95.0% | 94.7% | 92.8% | 90.4% | 90.1% | 90.6% | 89.6% | 80.1% | 45.4% | |
| -175.4% | -108.3% | -59.3% | -28.1% | -2.3% | 14.1% | 33.6% | 40.7% | 49.2% | 53.9% | 51.4% | 31.8% | |
| 20.0% | 15.6% | 11.8% | 9.4% | 7.3% | 4.2% | 3.1% | 2.7% | 2.2% | 1.9% | 1.4% | 4.9% |
Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.